A new publication involving abaloparatide was listed on November 1, 2026. The paper, titled "Parathyroid Hormone for Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis," appeared in the journal Oral Diseases. The publication is a systematic review and meta-analysis, a study type that compiles and analyzes existing research data. No specific findings, outcomes, or conclusions from the review have been detailed here. Abaloparatide remains an approved compound, and this entry simply records the appearance of this publication in the scientific literature. Readers interested in the full scope of the review, including its methodology and any conclusions drawn, are encouraged to consult the original article directly through the provided source. For additional context on abaloparatide, including its approved uses and background, readers can refer to the compound overview.
New Publication Reviews Parathyroid Hormone Use for MRONJ
See the full abaloparatide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42967897/